GlassScriptPhysician profile
Jeffrey L Todd
NPI 1700823713
$2,519.15
in general payments reported to CMS, 2019-2025
23 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $520 · 2021: $398 · 2022: $343 · 2023: $308 · 2024: $155 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $465.80 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $398.55 | 2021-2025 | Vraylar |
| Sanofi-Aventis U.S. LLC | $264.85 | 2019-2022 | |
| Pfizer INC. | $234.18 | 2019-2025 | |
| Lilly USA, LLC | $174.02 | 2019-2025 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $166.90 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.60 | 2025 | Caplyta |
| Allergan, INC. | $86.59 | 2019-2020 | |
| Astellas Pharma US INC | $83.55 | 2019 | |
| Axsome Therapeutics, INC. | $78.76 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.16 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $69.55 | 2023 | Crysvita |
| Janssen Pharmaceuticals, INC | $63.67 | 2019 | |
| Amgen INC. | $58.00 | 2021-2023 | Prolia |
| Glaxosmithkline, LLC. | $46.24 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $44.11 | 2020-2025 | Farxiga |
| Corcept Therapeutics | $24.49 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $20.51 | 2022 | |
| Sunovion Pharmaceuticals INC. | $19.30 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.84 | 2021 | |
| Dexcom, INC. | $17.39 | 2020 | |
| Sumitomo Pharma America, INC. | $12.62 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $12.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.